BioVie to Host KOL Event on Parkinson’s Drug BeziStirum and Phase 2 Progress

Apr 30, 2026

BioVie will host a virtual Key Opinion Leader (KOL) event featuring Dr. Suzanne de la Monte to discuss the mechanism of action of BeziStirum, an investigational therapy targeting neurodegenerative diseases including Parkinson’s. The session will provide insight into how the drug may impact disease pathology and progression.

The event will also include an update on BioVie’s ongoing Phase 2 clinical trial, offering investors and the medical community a closer look at the company’s development strategy and progress in treating Parkinson’s disease.

#BioVie
#Biotech
#Parkinsons
#NeurodegenerativeDisease
#ClinicalTrials
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Pharmaceuticals
#KOL
#BiotechInvesting
#Innovation
#Healthcare
#JaneKing
#NewsOut